Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders...

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

VintageCulture Aug. 30 at 1:07 AM

Watch NCRA 1000% runner potential, 0 shares to short 500% CTB $13 fair value MASSIVE MICRON TIES one of the most undervalued setups you will find 🚨🚨🚨🚨 $SILO $IQST $SKIL $CTNT !!!))

0 · Reply

TheBeautifulGopher Aug. 21 at 4:04 PM

$SILO sensei is too dumb will have to short this

0 · Reply

_Sensei_ Aug. 21 at 3:06 PM

$SILO looks good for a spike here, crypto theme

1 · Reply

rayankhader Aug. 21 at 12:53 PM

$SILO holding tight

0 · Reply

rayankhader Aug. 19 at 3:11 PM

$SILO I bought every dip I’m ready for you

0 · Reply

Adorno99 Aug. 19 at 3:03 PM

$SILO What is this down to if we use pre-RS numbers? 19 cents or thereabouts? Way oversold. Buying more and holding till 7-8 dollars

0 · Reply

rayankhader Aug. 19 at 1:44 PM

$SILO adding more

0 · Reply

Rastapasta22 Aug. 18 at 9:18 PM

$SILO they just reported shares confirmed the shelf is a resale.

0 · Reply

rayankhader Aug. 18 at 9:04 PM

$SILO new average $2.83 from $3.15

1 · Reply

flychicken1991 Aug. 18 at 8:57 PM

$SILO Positive (87%): shares can receive upward price support as the patent allowance reduces uncertainty around Canadian intellectual-property protection and increases the perceived strategic value of the PTSD treatment program. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/09dac7785250ea11?utm_source=stocktwits&utm_medium=story_url

0 · Reply

Silo Pharma receives notice of allowance from CIPO for PTSD treatment

Aug 18, 2026, 4:15 PM EDT - 13 days ago

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

2026-08-10T12:37:05.000Z - 21 days ago

Silo Pharma granted European patent covering PTSD therapy

Aug 6, 2026, 8:50 AM EDT - 25 days ago

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

2026-07-24T20:10:24.000Z - 5 weeks ago

Silo Pharma files to sell 1.91M shares of common stock for holders

Jul 21, 2026, 8:55 AM EDT - 5 weeks ago

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

2026-07-14T13:20:49.000Z - 6 weeks ago

Silo Pharma subsidiary QwikAgents joins AMD AI program

AMD

Jul 14, 2026, 8:55 AM EDT - 6 weeks ago

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

2026-07-10T12:16:17.000Z - 7 weeks ago

Silo Pharma prices $11.7M at-the-market offering at $6.45 per share

Jul 10, 2026, 8:00 AM EDT - 7 weeks ago

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jul 7, 2026, 8:11 AM EDT - 7 weeks ago

Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program

2026-06-29T20:50:29.000Z - 2 months ago

Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery

Jun 29, 2026, 4:15 PM EDT - 2 months ago

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

2026-06-23T15:29:15.000Z - 2 months ago

Silo Pharma reports positive stability data for stress treatment SPC-15

Jun 23, 2026, 8:17 AM EDT - 2 months ago

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

2026-06-18T12:33:09.000Z - 2 months ago

Silo Pharma regains compliance with Nasdaq min bid price requirement

Jun 18, 2026, 8:12 AM EDT - 2 months ago

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-06-02T23:50:11.000Z - 3 months ago

Silo Pharma Inc trading halted, news pending

2026-05-07T18:37:18.000Z - 4 months ago

Silo Pharma files provisional patent for ibogaine-based therapeutics

May 7, 2026, 8:05 AM EDT - 4 months ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Apr 29, 2026, 9:08 AM EDT - 4 months ago

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

2026-04-22T21:10:17.000Z - 4 months ago

Silo Pharma expands into AI technology with Qwikagents asset purchase

Apr 22, 2026, 4:15 PM EDT - 4 months ago

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

2026-04-06T20:20:47.000Z - 5 months ago

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

Apr 6, 2026, 4:15 PM EDT - 5 months ago

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

2026-02-23T21:38:21.000Z - 6 months ago

Silo Pharma announces $1M share repurchase program

Feb 23, 2026, 4:15 PM EST - 6 months ago

Silo Pharma Announces Share Buyback Program

Feb 18, 2026, 8:28 AM EST - 6 months ago

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Dec 30, 2025, 8:05 AM EST - 8 months ago

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Nov 17, 2025, 8:05 AM EST - 10 months ago

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

Oct 29, 2025, 8:25 AM EDT - 10 months ago

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Oct 23, 2025, 8:45 AM EDT - 11 months ago

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Oct 8, 2025, 8:45 AM EDT - 11 months ago

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Oct 6, 2025, 8:10 AM EDT - 11 months ago

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Oct 1, 2025, 4:20 PM EDT - 11 months ago

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 30, 2025, 8:02 AM EDT - 11 months ago

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 16, 2025, 8:11 AM EDT - 1 year ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Sep 9, 2025, 9:10 AM EDT - 1 year ago

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Sep 3, 2025, 8:25 AM EDT - 1 year ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Aug 21, 2025, 2:00 PM EDT - 1 year ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 19, 2025, 8:05 AM EDT - 1 year ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 5, 2025, 8:32 AM EDT - 1 year ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Jul 16, 2025, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 1 year ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 1 year ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 1 year ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 1 year ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 1 year ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 1 year ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 1 year ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 1 year ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 1 year ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

VintageCulture Aug. 30 at 1:07 AM

Watch NCRA 1000% runner potential, 0 shares to short 500% CTB $13 fair value MASSIVE MICRON TIES one of the most undervalued setups you will find 🚨🚨🚨🚨 $SILO $IQST $SKIL $CTNT !!!))

0 · Reply

TheBeautifulGopher Aug. 21 at 4:04 PM

$SILO sensei is too dumb will have to short this

0 · Reply

_Sensei_ Aug. 21 at 3:06 PM

$SILO looks good for a spike here, crypto theme

1 · Reply

rayankhader Aug. 21 at 12:53 PM

$SILO holding tight

0 · Reply

rayankhader Aug. 19 at 3:11 PM

$SILO I bought every dip I’m ready for you

0 · Reply

Adorno99 Aug. 19 at 3:03 PM

$SILO What is this down to if we use pre-RS numbers? 19 cents or thereabouts? Way oversold. Buying more and holding till 7-8 dollars

0 · Reply

rayankhader Aug. 19 at 1:44 PM

$SILO adding more

0 · Reply

Rastapasta22 Aug. 18 at 9:18 PM

$SILO they just reported shares confirmed the shelf is a resale.

0 · Reply

rayankhader Aug. 18 at 9:04 PM

$SILO new average $2.83 from $3.15

1 · Reply

flychicken1991 Aug. 18 at 8:57 PM

0 · Reply

rayankhader Aug. 18 at 8:38 PM

$SILO I bought the dip did you ? 👀

0 · Reply

TheBullsAndBears Aug. 18 at 8:29 PM

Too my profits from $TNON and moved into $SILO same news ah

0 · Reply

Alienfrom5thDimension Aug. 18 at 8:28 PM

$SILO they're probably selling stock into the news they've done it in the past I believe

0 · Reply

invstdwthaple Aug. 18 at 8:27 PM

$SILO Look like bagholders are going to keep this one from running up.

1 · Reply

rayankhader Aug. 18 at 8:26 PM

$SILO removing the sl and let it ride over night Lotto size I’m risking the money 👀

0 · Reply

rayankhader Aug. 18 at 8:22 PM

$SILO lotto size Sl $2.70

0 · Reply

rayankhader Aug. 18 at 8:21 PM

$SILO buying some here now 😴

0 · Reply

doctorslopadopolis Aug. 18 at 8:18 PM

$SILO wtf is it dropping and going up so fast

0 · Reply

AlertsAndNews Aug. 18 at 8:17 PM

$SILO more patent news, Canada on this one huh Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

0 · Reply

focafoca99 Aug. 17 at 8:22 PM

$SILO increased its authorized common shares to 250 million after shareholder approval.

0 · Reply

Adorno99 Aug. 12 at 11:48 AM

$SILO what's going on with this dawg today? Short attack? Don't see any bad news?

0 · Reply

Stock_Catcher Aug. 10 at 12:15 PM

$SILO Silo Pharma Granted European Patent Covering Novel PTSD Therapy

0 · Reply

Market Cap	4.03M
Revenue (ttm)	70,000.00
Net Income (ttm)	-4.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,042.86%
Debt to Equity Ratio	0.00

Volume	23,000
Avg Vol	236,506
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	10%
Beta	0.71
Analysts	Strong Sell
Price Target	$10.00